Value of combining biological age with assessment of individual frailty to optimize management of cancer treated with targeted therapies: model of chronic myeloid leukemia treated with tyrosine kinase inhibitors (BIO-TIMER trial)
Abstract Background In the era of targeted therapies, the influence of aging on cancer management varies from one patient to another. Assessing individual frailty using geriatric tools has its limitations, and is not appropriate for all patients especially the youngest one. Thus, assessing the compl...
保存先:
| 主要な著者: | , , , , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BMC
2024-05-01
|
| シリーズ: | BMC Cancer |
| 主題: | |
| オンライン･アクセス: | https://doi.org/10.1186/s12885-024-12415-2 |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|